

1645

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

COPY OF PAPERS
ORIGINALLY FILED

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598




June 6, 2002

p#4

RECEIVED

JUN 20 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on the date below:	
June 6, 2002	
Date	Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

Re: *U.S. Patent Application No. 10/025,187 entitled "A BARDET-BIEDL SUSCEPTIBILITY GENE AND USES THEREOF" by Val Sheffield et al.*
Our Reference: IOWA:034US


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references (C1-C15).

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/101102050/SLH.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642

SLH/cmb
Encl.: as noted

25173264.1

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Val Sheffield *et al.*

Serial No.: 10/025,187

Filed: December 18, 2001

For: A BARDET-BIEDL SUSCEPTIBILITY
GENE AND USES THEREOF



Group Art Unit: 1645

Examiner: Unknown

Atty. Dkt. No.: IOWA:034US

RECEIVED

JUN 20 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:	
June 6, 2002	
Date	
	Steven L. Highlander

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is hereby authorized to deduct said fees from Fulbright & Jaworski Deposit Account No.: 50-1212/10112050/SLH.

Applicants respectfully request that the listed documents be made of record in the present case.



Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: June 6, 2002

Form PTO-1449 (modified)	Atty. Docket No. IOWA:034US	Serial No. 107025187
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Val Sheffield <i>et al.</i>	
	Filing Date: December 18, 2001	
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

TECH CENTER 1600/2900

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bruford <i>et al.</i> , "Linkage mapping in 29 Bardet-Biedl syndrome families confirms loci in chromosomal regions 11q13, 15q22.3-q23, and 16q21," <i>Genomics</i> , 41:93-99, 1997.
	C2	Carmi <i>et al.</i> , "Phenotypic differences among patients with Bardet-Biedl syndrome linked to three different chromosome loci," <i>Am. J. Med. Genet.</i> , 59:199-203, 1995.
	C3	Carmi <i>et al.</i> , "Use of a DNA pooling strategy to identify a human obesity syndrome locus on chromosome 15," <i>Hum. Mol. Genet.</i> , 4:9-13, 1995.
	C4	Farag and Teebi, "Bardet-Biedl and Laurence-Moon syndromes in a mixed Arab population," <i>Clinical Genet.</i> , 33:78-82, 1988.
	C5	Farag and Teebi, "High incidence of Bardet Biedl syndrome among the Bedouin [letter]," <i>Clinical Genet.</i> , 36:463-464, 1989.
	C6	Katsanis <i>et al.</i> , "Mutations in MKKS cause obesity, retinal dystrophy and renal malformations associated with bardet-biedl syndrome," <i>Nat. Genet.</i> , 26:67-70, 2000.
	C7	Kwitek-Black <i>et al.</i> , "Linkage of Bardet-Biedl syndrome to chromosome 16q and evidence for non-allelic genetic heterogeneity," <i>Nature Genet.</i> , 5:392-396, 1993.
	C8	Leppert <i>et al.</i> , "Bardet-Biedl syndrome is linked to DNA markers on chromosome 11q and is genetically heterogeneous," <i>Nature Genet.</i> , 7:108-112, 1994.
	C9	Nishimura <i>et al.</i> , "The forkhead transcription factor gene FKHL7 is responsible for glaucoma phenotypes which map to 6p25," <i>Nature Genet.</i> , 19:140-147, 1998.

25118523.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

COPY OF PAPER
ORIGINAL FILED

Form PTO-1449 (modified)		Atty. Docket No. IOWA:034US	Serial No. 18,025,187
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Val Sheffield <i>et al.</i> JUN 17 2002	
		Filing Date: December 18, 2001	Group: 1645
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Sheffield <i>et al.</i> , "Identification of a Bardet-Biedl syndrome locus on chromosome 3 and evaluation of an efficient approach to homozygosity mapping," <i>Hum. Mol. Genet.</i> , 3(8):1331-1335, 1994.
	C11	Slavotinek <i>et al.</i> , "Mutations in MKKS cause bardet-biedl syndrome," <i>Nature Genet.</i> , 26:15-16, 2000.
	C12	Stone <i>et al.</i> , "Mutation of a gene encoding a putative chaperonin causes McKusick-Kaufman syndrome," <i>Nat. Genet.</i> , 25:79-82, 2000.
	C13	Swiderski <i>et al.</i> , "Expression pattern and in situ localization of the mouse homologue of the human MYCO (GLC1A) gene in adult brain," <i>Mol. Brain Res.</i> , 68:64-72, 1999.
	C14	Woods <i>et al.</i> , "Genetic heterogeneity of Bardet-Biedl syndrome in a distinct Canadian population: evidence for a fifth locus," <i>Genomics</i> , 55:2-9, 1999.
	C15	Young <i>et al.</i> , "A fifth locus for Bardet-Biedl syndrome maps to chromosome 2q31," <i>Am. J. Hum. Genet.</i> , 64:900-904, 1999.

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

JUN 20 2002

TECH CENTER 1600/2900

25118523.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)